A new device for cellulite reduction from El.En

El.En, Florence, Italy-based company leader on the laser market and listed in the Star segment of the Italian Stock Exchange, reports that its controlled company Cynosure, Inc. (El.En. retains control by the ownership of 23% of the shares), today announced that the U.S. Food and Drug Administration has cleared the Company’s Cellulaze Workstation for commercial distribution.

Nearly four years of clinical research puts Cellulaze in a class of its own: the only singletreatment aesthetic procedure clinically shown to reduce cellulite. Cellulaze also complements other body shaping technologies, such as the Smartlipo family of workstations.

“Cellulaze is the world’s first and only minimally invasive medical device designed to treat women who have struggled to eliminate cellulite through diet and exercise, or have tried the myriad of lotions and creams currently on the market,” said Cynosure President and Chief Executive Officer Michael Davin. “Unlike those products, Cellulaze is the only aesthetic device that directly treats the physiological structure of cellulite, providing clinically proven, results.”

An estimated 85% of women over the age of 20 have some form of cellulite – pockets of fat deposited just beneath the surface of the skin, around the hips, thighs, and buttocks, which produces an “orange-peel” or a “cottage cheese” appearance. The treatment of cellulite is a multibillion-dollar industry, according to market estimates.